Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma

NCT: NCT04123535 · TERMINATED

NCT IDNCT04123535
StatusTERMINATED
Start Date2020-01-23
Completion2026-04-30
SponsorMatthew Bucknor (OTHER)
First posted
Last updated

Brief Summary

This study is a single site, single-arm, feasibility study to evaluate the safety and efficacy of MRgFUS using the ExAblate 2100 System for the partial ablation of undifferentiated pleomorphic sarcomas.

Frequently Asked Questions

What is Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma?

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma is a clinical trial registered under NCT04123535. Current status: TERMINATED.

What is the status of NCT04123535?

The current status of NCT04123535 (Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma) is: TERMINATED.

When did Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma start?

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma started on 2020-01-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑